CAJ | 학술논문

目的：观察肝癌介入治疗中拉米夫定的预防性应用疗效。方法选取我院2010年9月~2012年8月收治的130例原发性肝癌患者，随机分为两组，对照组患者接受单纯介入治疗，实验组患者在介入治疗时辅以拉米夫定治疗。术后随访2年，对比分析两组患者治疗前后血清HBV-DNA水平的变化和死亡率的差异性。结果经过治疗后患者血清HBV-DNA水平均较治疗前升高，实验组升高幅度明显小于对照组，经t检验分析发现组间比较差异有统计学意义（P＜0.05）。随访期间实验组患者死亡率明显低于对照组，经卡方检验分析发现组间比较差异有统计学意义（P＜0.05）。结论肝癌介入治疗对乙肝病毒产生激发作用，抗病毒药物拉米夫定可预防和控制肝癌介入期间乙肝病毒活跃程度，从而保障抗肿瘤治疗效果，延长患者生存时间。
목적：관찰간암개입치료중랍미부정적예방성응용료효。방법선취아원2010년9월~2012년8월수치적130례원발성간암환자，수궤분위량조，대조조환자접수단순개입치료，실험조환자재개입치료시보이랍미부정치료。술후수방2년，대비분석량조환자치료전후혈청HBV-DNA수평적변화화사망솔적차이성。결과경과치료후환자혈청HBV-DNA수평균교치료전승고，실험조승고폭도명현소우대조조，경t검험분석발현조간비교차이유통계학의의（P＜0.05）。수방기간실험조환자사망솔명현저우대조조，경잡방검험분석발현조간비교차이유통계학의의（P＜0.05）。결론간암개입치료대을간병독산생격발작용，항병독약물랍미부정가예방화공제간암개입기간을간병독활약정도，종이보장항종류치료효과，연장환자생존시간。
Objective To observe efficacy of lamivudine of prophylactic use in the interventional therapy of liver cancer. Methods Selected 130 cases with primary liver cancer in our hospital from Sep 2010 to Aug 2012 ,randomly divided into two groups. The control group received simple intervention and experimental group received simple intervention combined with lamivudine. Patients were followed up 2 years after operation. Compared and analyzed serum HBV-DNA level changes and the differences in mortality rates of the patients before and after treatment in the two groups. Results Serum HBV-DNA level of patients was higher after treatment than before treatment,the range of experimental group increased significantly less than the control group,there was statistically significant difference between two groups after t test (P<0.05). Mortality of experimental group was significantly lower than the control group during the follow-up period ,there was statistically significant difference be-tween the two groups afterχ2 test (P<0.05). Conclusion The interventional therapy of liver cancer can stimulate hepatitis B virus (HBV),lamivudine can prevent and control the activity of HBV during intervention period of liver cancer,so as to safe-guard curative effect and prolong the survival time of patients.